Document is current
Any future updates will be listed below
-
Authors
Ziaee, Seyyed Mohyeddin
Nemati, Shiva
Kataria, Hardeep https://orcid.org/0000-0001-8413-0600
Jakova, Elisabet
Hosseini, Seyed Mojtaba
Ghelich, Pejman
McLeod, Graham
Tamayol, Ali https://orcid.org/0000-0003-1801-2889
Yong, V. Wee https://orcid.org/0000-0002-2600-3563
Karimi-Abdolrezaee, Soheila https://orcid.org/0000-0002-0683-2663
-
Funding
Funding for this research was provided by:
Multiple Sclerosis Society of Canada (EGID3742 and 1241879)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-191850)
Hillary Kaufman Memorial Funds in Multiple Sclerosis from the University of Manitoba.
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 1 April 2026
First Online: 11 May 2026
Competing interests
: S.K-A and H.K. are inventors on a patent entitled “USE OF NRG-1β1 FOR DETECTION AND/OR TREATMENT OF MULTIPLE SCLEROSIS” that is filed through three applications: A) Published PCT Application WO2022/056619 (completed), B) Published US Patent Application US2024/0009274, published January 11, 2024 (pending), C) Canadian Patent Application 3,191,086, date of national phase entry—February 27, 2023 (pending)—US Patent App. 18/043,199, 2024). This patent is related to the potential use of Nrg-1β1 as a treatment for multiple sclerosis. S.K-A is also an inventor on a provisional patent application titled “the NRG-1 CONDITIONAL KNOCKOUT MOUSE”, US Provisional Patent Application Serial Number 63/802,795, filed May 9, 2025 (pending). This provisional patent application is related to the Nrg-1 conditional knockout mouse model that is used in this article. The relevant interests regarding these two patent applications are managed by the University of Manitoba. All other authors declare no competing interests related to this work.
